Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Ovarian Neoplasms 5Triple Negative Breast Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Platinum-Refractory Fallopian Tube Carcinoma 1Pancreatic Neoplasms 1Neoplasms 1Melanoma 1Lymphoma 1Liposarcoma 1Fallopian Tube Neoplasms 1Carcinoma, Squamous Cell 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

trametinib 2olaparib 1glembatumumab vedotin 1durvalumab 1cediranib 1Vorinostat 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1CR011-vcMMAE 1Biopsy, Fine-Needle 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Uveal Melanoma × olaparib × Clear all
NCT05482074 2024-01-19

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡